

Two transcripts encode rat cytochrome b_5 reductase

(cDNA/erythrocytes/liver/membrane proteins/RNase A mapping)

GRAZIA PIETRINI, PAOLA CARRERA, AND NICA BORGESSE

Consiglio Nazionale delle Ricerche, Center for Cytopharmacology, University of Milan, 20129 Milan, Italy

Communicated by George E. Palade, June 6, 1988

ABSTRACT A cDNA expression library in λ gt11 was screened with affinity-purified polyclonal anti-rat cytochrome b_5 reductase antibodies. One positive clone out of 450,000 clones was isolated and found to be incomplete. This clone was used to rescreen the library, and a second, overlapping clone that contained the entire coding sequence was isolated. RNA gel blots showed that the two overlapping clones contained $\approx 90\%$ of the reductase mRNA sequence. Sequencing data showed (i) that rat reductase has a 93% sequence similarity with bovine and human reductase and (ii) that reductase is not synthesized as a high molecular weight precursor. Results of Southern blot analysis were consistent with the hypothesis that a single gene codes for the soluble and membrane-bound (microsomal and mitochondrial) forms of the reductase, present in erythrocytes and liver, respectively. The cloned cDNA was used to study reductase transcripts in liver and reticulocytes. Two antisense RNA probes that together covered the entire coding region and part of the noncoding region of reductase mRNA were used in RNase A protection experiments. These probes detected only one transcript in liver, suggesting that endoplasmic reticulum and mitochondrial reductase are translated from the same mRNA. In contrast, two transcripts were detected in reticulocytes, one of which mismatched the liver probe ≈ 30 nucleotides downstream from the initiation codon. Since the soluble and membrane form of the reductase are known to differ at the N terminus, we suggest that this second transcript encodes soluble reductase.

NADH-cytochrome b_5 reductase (NADH:ferricytochrome- b_5 oxidoreductase, EC 1.6.2.2) is an enzyme that exists as an integral membrane component, on endoplasmic reticulum and outer mitochondrial membranes of liver (1, 2) and many other tissues (3), and as a soluble protein, in erythrocytes (4). Genetic studies in man suggest that the membrane-bound and soluble forms are products of the same gene (5).

Structural studies on the membrane-bound and soluble forms of the reductase in a variety of species have demonstrated (i) that the membrane-bound form (300 amino acids) consists of a large cytoplasmic domain (≈ 275 amino acids) and a short N-terminal membrane anchor that contains a myristic acid covalently attached to the N-terminal glycine (6) and (ii) that the soluble form, purified from human erythrocytes, has a primary structure identical to the cytoplasmic domain (comprising the 276 carboxyl-terminal amino acids) of its membrane-bound counterpart (7, 8). Thus, it has been suggested that the soluble form is derived from the membrane enzyme by posttranslational proteolysis during the maturation of erythroblasts (4, 8).

We have been interested in elucidating the biogenetic relationships between the differently localized reductase forms. Studies in rat liver have demonstrated (i) that the membrane-bound form is synthesized on free polysomes (9) and inserted posttranslationally and independently into en-

doplasmic reticulum and outer mitochondrial membranes (10, 11) and (ii) that the mitochondrial and endoplasmic reticulum forms cannot be distinguished by peptide mapping or immunological criteria (12). These data suggested that an identical protein is targeted independently to two membrane systems. In addition, our work on the rat soluble enzyme showed that its apparent molecular weight was very close to that of its membrane-bound counterpart (13), suggesting that proteolytic processing might not be the mechanism responsible for its generation. In the present study, we have carried our investigation further by studying the transcripts encoding cytochrome b_5 reductase in two cell types—liver cells and reticulocytes—that predominantly contain the membrane-bound and soluble reductase, respectively. To this purpose, we have cloned a cDNA containing the entire reductase coding sequence* that we have used as probe in RNA gel blotting and RNase A protection experiments.

MATERIALS AND METHODS

General. Most of the methods used in this study are described in Maniatis *et al.* (14). Recombinant λ gt11 phage DNA was prepared from lysogenic host bacteria as described by Davis *et al.* (15). DNA fragments, purified by agarose gel electrophoresis, to be used as probes for plaque hybridization or for RNA gel or Southern blots were labeled by the hexanucleotide random-priming method (16). DNA sequencing was carried out by the dideoxy chain-termination method (17) by using the kits of Promega Biotec (Madison, WI) or Amersham for double-stranded (pGEM-3) or single-stranded (M13) recombinant vectors, respectively. RNA was prepared by the guanidine isothiocyanate/CsCl procedure (18) from livers or reticulocyte-enriched preparations (see below) obtained from male Sprague-Dawley rats [150–200 g (body weight)]. Poly(A)⁺ RNA was purified from total RNA by poly(U) paper affinity chromatography (19) by using Hybond mAP (Amersham).

Immunological Screening of the cDNA Library. A rat liver cDNA expression library in λ gt11 was kindly provided by M. Mueckler (20). Rabbit affinity-purified anti-rat cytochrome b_5 reductase antibodies (2), preadsorbed with lysates of plating bacteria (*Escherichia coli* Y1090), were used for immunological screening of the library as described by Huynh *et al.* (21), except for radioimmunostaining of the nitrocellulose replicas that was performed under the same conditions as those used for immunoblotting in our laboratory (2, 13).

Rat Reticulocyte-Enriched Preparation. Male Sprague-Dawley rats, made anemic by phenylhydrazine treatment as described (13), were sacrificed by decapitation. The blood was collected into a beaker containing 0.1 M sodium phosphate and 50 mM EDTA (pH 7) and passed through a microcrystalline cellulose- α -cellulose column (Sigma). We

Abbreviation: nt, nucleotide(s).

*The sequence reported in this paper is being deposited in the EMBL/GenBank data base (IntelliGenetics, Mountain View, CA, and Eur. Mol. Biol. Lab., Heidelberg) (accession no. J03867).

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

have found that this procedure, which is known to remove leukocytes from human blood (22), is effective with rat blood as well [removal of 96% of the leukocytes (23)]. The erythrocyte preparation was then washed twice with isotonic phosphate-buffered saline to remove plasma, and the percentage of reticulocytes in the final preparation was determined on smears after staining with brilliant cresyl blue. Between 56% and 67% of the erythrocytes in these preparations were reticulocytes.

Single-Stranded RNA Probes. The recombinant DNA isolated from the library by plaque hybridization yielded two fragments of ≈ 500 and ≈ 900 base pairs (bp), respectively, after *Eco*RI digestion (see *Results*). These fragments were inserted into the *Eco*RI site of pGEM-3 (Promega Biotec), yielding plasmids pG500 and pG900, respectively. Depending on the orientation of the insert, these plasmids generated sense or antisense transcripts, when transcribed from the T7 promoter. The templates were truncated at sites downstream from the cloned insert relative to the T7 promoter but within the vector polylinker region to yield linear molecules: pG500 with *Xba* I, and pG900 with *Bam*HI. pG500 was also truncated at an internal site of the insert DNA with *Ava* I [139 nucleotides (nt) from the 5' end]. The linearized templates were used for the synthesis of high-specific-activity [32 P]GTP-labeled RNA (24). The labeled RNA was purified by DNase treatment and then by phenol extraction and ammonium acetate/ethanol precipitation (25).

RNase A Protection Experiments. The RNase protection procedure was performed as described by Zinn *et al.* (26) with a mixture of RNase A and T1 to digest unhybridized probe. Protected probe fragments were analyzed on 6% sequencing gels. Labeled RNA molecular size markers were synthesized from the Riboprobe Gemini positive control template (Promega Biotec) by using SP6 and T7 polymerase.

RESULTS

Cloning and Sequence Analysis of Rat Liver Cytochrome b_5 Reductase cDNA. To search for a cDNA clone specifying cytochrome b_5 reductase, a rat liver cDNA library in λ gt11 (20) was screened with polyclonal antireductase antibodies. Out of 450,000 plaques, 1 plaque gave a clearly positive signal. Digestion of the purified recombinant DNA with *Eco*RI released a 1500-bp fragment, which was purified and subcloned into pGEM-3. Partial sequence analysis of this clone (referred to as the first clone) revealed at one of its extremities a reading frame that corresponded to a sequence identical to amino acids 140–159 of bovine liver microsomal reductase (6). The other extremity of the clone did not contain a poly(A) tail. These data, although establishing the identity of our clone, also demonstrated that it was lacking the 5'-terminal portion of the coding region as well as the 3' terminus of reductase cDNA (Fig. 1).

To search for a clone containing the entire coding sequence for the reductase, the 5'-terminal *Eco*RI–*Pvu* II fragment of the first clone (see Fig. 1) was used to rescreen the λ gt11 library by plaque hybridization. Six positive clones out of 450,000 plaques were detected. Three of these clones released two fragments upon *Eco*RI digestion, indicating that an internal *Eco*RI site was present in reductase cDNA. One of these clones (referred to here as the second clone), consisting of two fragments of ≈ 900 and ≈ 500 bp, was selected for further analysis. The two fragments were subcloned separately into pGEM-3 to obtain plasmids pG900 and pG500, respectively, and subjected to restriction mapping and sequence analysis. As shown in Fig. 1, the ≈ 900 -bp fragment was found to correspond to the 5'-terminal ≈ 900 nt of the first clone, whereas sequence analysis of the ≈ 500 -bp fragment revealed that it contained the initiator codon of reductase mRNA (see the sequence analysis below).




FIG. 1. Relationship between the two reductase cDNA clones isolated in this study and the encoded protein. The insert isolated from the first clone specified the C-terminal portion of the reductase and contained in addition ≈ 1000 noncoding nucleotides. The second overlapping clone contained the entire coding sequence. This clone contained an internal *Eco*RI site. The two fragments released from λ gt11 by *Eco*RI digestion were subcloned separately into pGEM-3 to obtain clones pG500 and pG900. The open box represents the coding region, and the single line represents the noncoding regions of the clones. The positions of the *Pvu* II and *Ava* I sites are indicated.

The sequence of the entire second clone (≈ 500 -bp plus ≈ 900 -bp fragments) is shown in Fig. 2. An AUG codon at 34 nt from the 5' terminus of the clone, placed within the consensus context for initiation (27), was followed by an open reading frame corresponding to a protein with 93% similarity to the bovine liver protein (6) and to the portion of the human protein whose sequence is known (8). A termination codon at position 1, in frame with the AUG at position 34, ruled out the possibility of alternative initiation sites in liver reductase mRNA, upstream to position 1 of our clone.

The cloned cDNA was used as probe to determine the size of reductase mRNA in liver and reticulocytes by RNA gel blotting (Fig. 3). The probe hybridized to a ≈ 2200 -nt species in liver and to a slightly smaller RNA (2050 nt) in reticulocytes. Thus, the two clones that we isolated contained $\approx 90\%$ of the sequence of liver reductase mRNA. Longer exposures of blots, like the one shown in Fig. 3, failed to reveal a reticulocyte band comigrating with the liver species (data not shown).

RNase A Protection Experiments. pG500 and pG900 (see Fig. 1) were used to generate uniformly labeled antisense RNA probes. These two probes, which covered the 5'-terminal and 3'-terminal halves of the coding region of reductase mRNA, respectively, were annealed with total liver, reticulocyte, or yeast RNA and then treated with a mixture of RNases to digest the unhybridized probe. The RNase-resistant products were analyzed on sequencing gels. The results obtained with pG900 are shown in Fig. 4A. The probe was protected along its entire length (894 nt) by liver (lane 2) and by reticulocyte (lane 3) RNA. The small difference in length between the protected fragment and the probe not exposed to RNase digestion (lane 1) is due to the removal of extraneous RNA at the extremities of the probe generated by transcription of a portion of pGEM-3 polylinker. Yeast RNA, used as control, was incapable of protecting the probe (lane 4).

These results indicated that the portion of reductase mRNA encoding amino acids 140–300 as well as the first 422 nt of the 3'-noncoding region is the same in reticulocytes and liver. A different result was obtained with the probe generated from pG500 (Fig. 4B). As in the case of pG900, this probe was protected along its entire length (454 nt) by liver (lane 2) and not protected by yeast RNA (lane 4). Instead, when reticulocyte RNA was used, in addition to the protected probe of 454 nt a band of ≈ 390 nt appeared (lane 3), suggesting that reticulocytes contain two reductase mRNAs, one with a coding sequence identical to that of liver and the other differing from the liver transcript. Doubling the RNase

1	TAGAACGGTG	CCACCCTGT	CTTCTCGCC	ACC	ATG	GGG	GCC	CAG	CTG	AGC	ACG	TTG	AGC	CGA	GTG	GTA	CTC	TCC	CCG	GTC	TGG	TTC	GTC	TAC					
r					MET	Gly	Ala	Gln	Leu	Ser	Thr	Leu	Ser	Arg	Val	Val	Leu	Ser	Pro	Val	Trp	Phe	Val	Tyr					
s					GLY	-	-	-	-	-	-	-	Gly	His	-	-	-	-	-	Leu	-	-	-	Leu					
h												LEU	Gly	His	Met	-	-	-	Phe	-	-	-	-	Leu					
94	AGC	CTC	TTC	ATG	AAG	CTG	TTT	CAG	CGC	TCC	TCA	CGG	GCC	ATC	ACC	CTC	GAG	AAC	CCC	GAC	ATC	AAG	TAC	CCT	CTG	CGG	CTC	ATC	GAC
r	Ser	Leu	Phe	Met	Lys	Leu	Phe	Gln	Arg	Ser	Ser	Pro	Ala	Ile	Thr	Leu	Glu	Asn	Pro	Asp	Ile	Lys	Tyr	Pro	Leu	Arg	Leu	Ile	Asp
s	-	-	Ile	-	-	-	-	-	-	-	Thr	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
h	-	-	Leu	-	-	-	-	-	-	-	Thr	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
181	AAG	GAG	ATT	ATC	AGC	CAT	GAC	ACT	CGG	CGC	TTC	CGA	TTT	GCA	CTC	CCT	TCG	CCC	CAG	CAC	ATC	CTG	GGC	CTT	CCT	ATC	GGC	CAG	CAC
r	Lys	Glu	Ile	Ile	Ser	His	Asp	Thr	Arg	Arg	Phe	Arg	Phe	Ala	Leu	Pro	Ser	Pro	Gln	His	Ile	Leu	Gly	Leu	Pro	Ile	Gly	Gln	His
s	-	-	Val	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Glu	-	-	-	-	-	-	Val	-	-
h	Arg	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Val	-	-	-
268	ATC	TAC	CTC	TCC	ACC	AGG	ATC	GAT	GGC	AAC	TTG	GTC	ATT	CGT	CCC	TAC	ACC	CCT	GTG	TCT	AGT	GAT	GAT	GAC	AAG	GGC	CTT	GTG	GAC
r	Ile	Tyr	Leu	Ser	Thr	Arg	Ile	Asp	Gly	Leu	Val	Ile	Arg	Pro	Tyr	Thr	Pro	Val	Ser	Ser	Asp	Asp	Asp	Lys	Gly	Leu	Val	Asp	
s	-	-	-	Ala	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Phe	-
h	-	-	-	Ala	-	-	-	-	-	-	Val	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Phe	-
355	TTG	GTG	GTC	AAG	GTT	TAC	TTC	AAG	GAC	ACG	CAT	CCC	AAG	TTT	CCA	GCT	GGA	GGG	AAA	ATG	TCT	CAG	TAC	CTG	GAA	AAC	ATG	AAT	ATT
r	Leu	Val	Val	Lys	Val	Tyr	Phe	Lys	Asp	Thr	His	Pro	Lys	Phe	Pro	Ala	Gly	Gly	Lys	Met	Ser	Gln	Tyr	Leu	Glu	Asn	Met	Asn	Ile
s	-	-	-	Ile	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
h	-	-	-	Ile	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
442	GGA	GAC	ACC	ATT	GAA	TTC	CGG	GGC	CCC	AAT	GGG	CTA	CTG	GTC	TAC	CAG	GGC	AAA	GGG	AAG	TTC	GCC	ATC	CGT	GCA	GAC	AAG	AAG	TCC
r	Gly	Asp	Thr	Ile	Glu	Phe	Arg	Gly	Pro	Asn	Gly	Leu	Leu	Val	Tyr	Gln	Gly	Lys	Gly	Lys	Phe	Ala	Ile	Arg	Ala	Asp	Lys	Lys	Ser
s	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
h	-	-	-	-	-	-	-	-	-	Ser	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
529	AAC	CCT	GTT	GTC	AGG	ACG	GTG	AAG	TCT	GTA	GGC	ATG	ATT	GCA	GGA	GGG	ACA	GGC	ATC	ACC	CCA	ATG	CTG	CAG	GTG	ATC	CGA	GCC	GTC
r	Asn	Pro	Val	Val	Arg	Thr	Val	Lys	Ser	Val	Gly	Met	Ile	Ala	Gly	Gly	Thr	Gly	Ile	Thr	Pro	Met	Leu	Gln	Val	Ile	Arg	Ala	Val
s	Asp	-	-	Ile	Lys	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
h	-	-	-	Ile	Lys	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
616	TTG	AAG	GAC	CCG	AAC	GAC	CAC	ACT	GTG	TGC	TAT	CTG	CTC	TTC	GCC	AAC	CAG	TCC	GAG	AAA	GAC	ATC	CTG	CTG	CGG	CCT	GAG	CTG	GAG
r	Leu	Lys	Asp	Pro	Asn	Asp	His	Thr	Val	Cys	Tyr	Leu	Leu	Phe	Ala	Asn	Gln	Ser	Glu	Lys	Asp	Ile	Leu	Leu	Arg	Pro	Glu	Leu	Glu
s	Met	-	-	-	Asp	-	-	-	-	-	His	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
h	Met	-	-	-	Asp	-	-	-	-	-	His	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
703	GAA	CTG	AGG	AAC	GAA	CAT	TCT	TCT	CGC	TTC	AAG	CTC	TGG	TAC	ACA	GTG	GAC	AAA	GCC	CCC	GAT	GCC	TGG	GAC	TAT	AGC	CAA	GGC	TTC
r	Glu	Leu	Arg	Asn	Glu	His	Ser	Ser	Arg	Phe	Lys	Leu	Trp	Tyr	Thr	Val	Asp	Lys	Ala	Pro	Asp	Ala	Trp	Asp	Tyr	Ser	Gln	Gly	Phe
s	-	-	-	Asp	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
h	-	-	-	Lys	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
790	GTG	AAT	GAG	GAG	ATG	ATC	AGG	GAC	CAT	CTT	CCA	CCT	CCT	GGG	GAG	GAG	ACA	CTG	ATA	CTG	ATG	TGT	GGA	CCC	CCA	CCG	ATG	ATC	CAG
r	Val	Asn	Glu	Glu	Met	Ile	Arg	Asp	His	Leu	Pro	Pro	Pro	Gly	Glu	Glu	Thr	Leu	Ile	Leu	Met	Cys	Gly	Pro	Pro	Pro	Met	Ile	Gln
s	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
h	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
877	TTT	GCC	TGT	TTG	CCA	AAC	CTG	GAG	CGT	GTG	GGC	CAT	CCC	AAG	GAG	CGA	TGC	TTC	ACC	TTC	TGATGGCTGG	ATGCTGGCCA	CTCCCATGCC						
r	Phe	Ala	Cys	Leu	Pro	Asn	Leu	Glu	Arg	Val	Gly	His	Pro	Lys	Glu	Arg	Cys	Phe	Thr	Phe									
s	Tyr	-	-	-	-	-	-	Asp	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
h	Tyr	-	-	-	-	-	-	Asp	His	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
967	TGCTGTAC	GCACCTAC	CAACACCA	CAACACCTT	CCACCCCTTC	CTTCCCCTTC	ACTGTCCTT	ACCTGACAT	ATGCCACAT	CCATGCTGGG	GCCTGGGTTT																		
1067	AGCCTGGCCT	GCACGACCT	GGTCATCCAG	CTGTACTGGC	CCCTGAGGGG	CCCCTTGGG	AGCAGGCTG	TGTATCAGT	GGCTTCTGTT	GACCACTTC																			
1167	TGAATAGGCT	TCTGTCTGGT	ACTAAGTGGC	CATTACCAGA	GATGGTCCAT	GACCACCCCT	TTATACACAC	ACACATACAC	ATACAGAGAC	AGAGAGACAG																			
1267	AGAGACAGAG	ATAGACAGAG	ATAGACAGAG	AGACAGATAC	AGACATAGAG	ACAGAGAGAG	AAGAGAGAGA	GAGGAGAGAG	AG																				

Fig. 2. Nucleotide sequence of the second clone and deduced amino acid sequence of rat liver cytochrome *b₅* reductase. The ≈ 500 -bp fragment was sequenced in pGEM-3, by using the T7 and SP6 promoter primers (Promega Biotec). The ≈ 900 -bp fragment was sequenced after subcloning appropriate overlapping restriction fragments into M13. Numbers on the left refer to nucleotide positions. Nucleotides contributed by *EcoRI* linkers, present at the extremities of the clone, are not included in this figure. The deduced amino acid sequence of the rat protein is shown on line r. The positions at which the bovine liver (line s, ref. 6) and human liver (line h, ref. 8) reductase differ from the rat protein are shown. Positions of identity are indicated by the dashes. The first amino acid of each sequence is indicated in capital letters.

A concentration did not alter the ratio between these two protected fragments (data not shown).

To determine at which extremity of the probe the mismatch with reticulocyte reductase mRNA was localized, an antisense probe lacking 139 nt at the 5' end (*Ava* I-digested pG500; see Fig. 1) was hybridized to reticulocyte RNA. As




Fig. 3. RNA gel blot of liver and reticulocyte RNA hybridized with reductase probe. RNA molecules were separated on 1% agarose gels containing 2.2 M formaldehyde and Mops buffer (28). Lanes: 1, 1 μ g of poly(A)⁺ liver RNA; 2, 8.5 μ g of total reticulocyte RNA. The blot was probed with the *EcoRI*-*Pvu* II fragment of the first clone (see Fig. 1). Hybridization, in 0.75 M NaCl plus 50% (vol/vol) formamide at 42°C, and washing, in 0.015 M NaCl at 60°C, were under high-stringency conditions. 28S and 18S indicate the positions of rRNA markers.

shown in Fig. 4C, lane 3, after RNase digestion, only one fragment was obtained, corresponding to the entire length of the probe (315 nt). Thus, the mismatch between the liver pG500 probe and the second reticulocyte mRNA species is localized at the 5' extremity of the probe close to nt 64—i.e., within the coding region ≈ 30 nt from the start codon.

In all these experiments, controls were carried out with sense, instead of antisense, probes. As expected, no protection was obtained (data not shown).

Southern Blot Analysis. The ≈ 500 - and ≈ 900 -nt fragments were used as probes in Southern blots of rat genomic DNA, digested with *EcoRI* or *Bam*HI (Fig. 5). Since the two probes are generated by cleavage with *EcoRI* at a site within the reductase coding sequence, they were expected to recognize different fragments of genomic DNA digested by *EcoRI*. In fact, the ≈ 500 -nt probe recognized a band of 6400 bp (Fig. 5A, lane 1), whereas the ≈ 900 -nt probe hybridized to a band of 950 bp (Fig. 5B, lane 1). In contrast, both probes recognized the same 14,000-bp band after *Bam*HI digestion of genomic DNA (lanes 2 of A and B). These results strengthen the hypothesis that a single gene codes for the reductase.

DISCUSSION

In this study, we have isolated a cDNA clone containing the entire coding sequence of rat liver cytochrome *b₅* reductase that we have used as probe to study the transcripts encoding the reductase in liver and in reticulocytes. A cDNA encoding human reductase has been isolated by others (8); however,




FIG. 4. Analysis of liver and reticulocyte reductase mRNA by RNase mapping. Total liver RNA (6 μg) (lanes 2), 12 μg of total reticulocyte RNA (lanes 3), or 12 μg of total yeast RNA (lanes 4) were hybridized to 0.3×10^6 cpm (≈ 0.3 ng) of pG900 antisense RNA probe (A), pG500 antisense RNA probe (B), or a 324-nt antisense RNA probe transcribed from pG500 linearized by *Ava* I digestion (C). The samples, in a final volume of 330 μl , were then digested for 15 min at 30°C with RNase A (36 $\mu\text{g}/\text{ml}$) plus RNase T1 (0.084 unit/ μg of RNA) in A and B and with RNase A (72 $\mu\text{g}/\text{ml}$) plus RNase T1 (0.084 unit/ μg of RNA) in C. The RNase-resistant products were size-fractionated on 6% polyacrylamide/urea sequencing gels and detected by autoradiography with intensifying screens. Numbers on the left indicate positions and length (in nt) of RNA markers synthesized from Gemini-positive control template and from truncated pG500 and pG900 plasmids. Undigested probes are shown in lanes 1.

this clone lacked the extreme 5' terminus of the coding region.

The sequence analysis of the cloned cDNA confirmed that the reductase is a highly conserved protein (8) and, in addition, showed that the primary translation product differs at its N terminus from the mature protein [sequenced in bovine liver (6)] only by the presence of the initiator methionine. Thus, the reductase is not synthesized as a precursor with an extra peptide destined for removal, as suggested also by results obtained in cell-free translation systems (11, 29).

Cytochrome *b₅* reductase is present in three locations: as an integral constituent of endoplasmic reticulum and outer mitochondrial membranes and as a soluble protein in the cytoplasm of erythrocytes. Genetic data in humans (5), as well as the Southern blot analysis presented in the present paper, strongly support the hypothesis that a single gene codes for this enzyme. To pursue our studies on the biogenetic relationships between the reductase in its different locations, we analyzed its transcripts with the RNase A mapping technique (26). This technique seems to be particularly appropriate for picking up small differences between nucleic acid molecules since it can detect even point muta-




FIG. 5. Southern blot of rat genomic DNA hybridized with reductase probes. DNA (20 μg) was digested with *Eco*RI (lanes 1) or with *Bam*HI (lanes 2) and separated on a 0.7% agarose gel. Hybridization was carried out, as specified in Fig. 3, with the ≈ 500 -bp (A) or the ≈ 900 -bp (B) probe. Numbers on the left indicate positions and length in bp ($\times 10^{-3}$) of *Bst*EII-digested and undigested phage DNA markers.

tions (26). The results obtained with liver RNA indicate that only one reductase sequence is present in the transcripts of that tissue. If a second liver mRNA coding for mitochondrial reductase did exist, it should have been present in sufficient concentration to be detected in our experiments. In fact, given the known abundance of liver mitochondrial reductase (2) and its rate of synthesis compared to microsomal reductase (10), a hypothetical mRNA coding for the mitochondrial form would represent $\approx 20\%$ of the reductase encoding transcripts of the liver cell. Moreover, if mitochondrial and microsomal reductase are products of the same gene, as suggested by the genetic data (5), differences between the two forms would be expected to be restricted to limited portions of the enzyme. Thus, protected fragments resulting from partial hybridization between the probes and a putative second liver transcript should have been detected. It seems, therefore, reasonable to conclude that only one membrane form of reductase exists in liver and that the same reductase is targeted to both outer mitochondrial and endoplasmic reticulum membranes. This situation is in contrast with that of cytochrome *b₅*, for which a distinct mitochondrial form has been identified (30). The mechanism of the recognition between the reductase and these two membranes is not yet understood. However, the insertion of the reductase cannot be explained simply by a nonspecific partitioning of its hydrophobic domain into any lipid bilayer, since it is present at low concentrations, or not at all, on all organelles of the hepatocyte except endoplasmic reticulum and outer mitochondrial membranes (2).

When RNase protection experiments were carried out with reticulocyte RNA, quite a different result from that in liver was obtained. In fact, two transcripts were detected, one of which contained a region of mismatch with the 5'-terminal liver probe. This mismatch was located at nt 60–65 of the probe, ≈ 30 nt downstream of the initiator AUG. We do not know how far to the left of this position the mismatch extended; however, our data indicate that the region of diversity between the second reticulocyte mRNA and the liver probe must be large (>30 nt). In fact, if the difference had been restricted to a few nucleotides, a second protected fragment of ≈ 60 nt would have been generated by RNase

digestion. However, in gels designed to detect small molecules (≥ 30 nt), no additional protected fragments were observed, indicating that the region of the probe upstream to positions 60–65 had been extensively digested (results not shown).

Since the difference between the soluble and membrane form of the reductase is known to be located at the N terminus (7, 8) and the soluble form is present in erythrocytes and absent in liver, we suggest that the extra transcript present in reticulocytes encodes soluble cytochrome *b₅* reductase. This transcript could be generated from the reductase gene by an alternative promoter and/or alternative splicing mechanism. An inconsistency of this hypothesis with previous work is that human soluble reductase has been reported to have as its N-terminal amino acid phenylalanine-26 of the membrane form (7), corresponding to the TTT codon at position 112 of our clone. However, it is possible that soluble reductase is larger than previously thought and may have been partially degraded during purification before sequencing (7), as suggested also by our results on rat soluble reductase (13).

An unexpected finding was that the single band seen on RNA gel blots of reticulocyte RNA appeared to contain two molecules, one completely matched to the liver probes employed. It is, in fact, unlikely that the presence of the larger protected fragment observed in RNase A protection experiments was an artifact due to incomplete digestion of the probe, because the polylinker region of the probe was completely digested and because increasing the concentration of RNase A did not alter the ratio between the two protected fragments. Thus, two transcripts, very similar in size, were probably responsible for the generation of these two protected fragments. Since the reticulocyte "liver-type" transcript completely protected the liver probes, its smaller size compared to that of its counterpart in liver (seen on RNA gel blots) must be explained by the presence of a difference outside of the sequence covered by the probes, possibly at the 3' terminus of the transcripts.

The possibility should also be considered that the liver-type RNA present in reticulocyte RNA preparations was contributed by the small amount of contaminating leukocytes in our erythrocyte preparations; however, this would imply an enormously high concentration of reductase mRNA in leukocytes (>1000 times higher than in liver), a situation difficult to reconcile with the reported levels of reductase protein in leukocytes (5, 13). It remains surprising that reticulocytes contain so much liver-type transcript, since >90% of reticulocyte reductase is soluble (13). The liver-type transcript, coding for the membrane form, may represent a remnant from more immature erythrocytes. Indeed, membrane-bound reductase has been shown to be present in Friend erythroleukemia cells (31). In any case, the presence in reticulocytes of a reductase-encoding transcript that differs from the liver mRNA in the extreme 5'-terminal portion of the coding sequence supports the idea that soluble reductase is translated from a tissue-specific mRNA.

We thank Drs. M. Mueckler and G. Cairo for their kind gifts of a rat liver cDNA library in λ gt11 and a preparation of rat genomic DNA, respectively. We thank Mr. P. Tinelli, Mr. F. Crippa, and Mr. C. Sala for technical collaboration in the preparation of the illustrations; Drs. D. Fesce, G. Fumagalli, and C. Laforluna for computer advice; Dr. L. Mori for helpful advice on Southern blotting; and Dr.

F. Clementi for reading the manuscript. This work was partially supported by Consiglio Nazionale delle Ricerche, Progetto Finalizzato "Ingegneria genetica e basi molecolari delle malattie ereditarie."

1. Sottocasa, G. L., Kuylentierna, B., Ernster, L. & Bergstrand, A. (1967) *J. Cell Biol.* **32**, 415–438.
2. Borgese, N. & Pietrini, G. (1986) *Biochem. J.* **239**, 393–403.
3. Tamura, M., Yubisui, T., Takeshita, M., Kawabata, S., Miyata, T. & Iwanaga, S. (1987) *J. Biochem. (Tokyo)* **101**, 1147–1159.
4. Hultquist, D. E., Slaughter, S. R., Douglas, R. H., Sannes, L. J. & Sagavian, G. G. (1978) *Prog. Clin. Biol. Res.* **21**, 199–211.
5. Leroux, A., Junien, C., Kaplan, J.-C. & Bamberger, J. (1975) *Nature (London)* **258**, 619–620.
6. Ozols, J., Korza, G., Heinemann, F. S., Hediger, M. A. & Strittmatter, P. (1985) *J. Biol. Chem.* **260**, 11953–11961.
7. Yubisui, T., Miyata, T., Iwanaga, S., Tamura, M. & Takeshita, M. (1986) *J. Biochem. (Tokyo)* **99**, 407–422.
8. Yubisui, T., Naitoh, Y., Zenno, S., Tamura, M., Takeshita, M. & Sakaki, Y. (1987) *Proc. Natl. Acad. Sci. USA* **84**, 3609–3613.
9. Borgese, N. & Gaetani, S. (1980) *FEBS Lett.* **112**, 216–220.
10. Borgese, N., Pietrini, G. & Meldolesi, J. (1980) *J. Cell Biol.* **86**, 38–45.
11. Borgese, N. & Gaetani, S. (1983) *EMBO J.* **2**, 1263–1269.
12. Meldolesi, J., Corte, G., Pietrini, G. & Borgese, N. (1980) *J. Cell Biol.* **85**, 516–526.
13. Borgese, N., Macconi, D., Parola, L. & Pietrini, G. (1982) *J. Biol. Chem.* **257**, 13854–13861.
14. Maniatis, T., Fritsch, E. F. & Sambrook, J. (1982) *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Lab., Cold Spring Harbor, NY).
15. Davis, R. W., Botstein, D. & Roth, J. R. (1980) *Advanced Bacterial Genetics* (Cold Spring Harbor Lab., Cold Spring Harbor, NY).
16. Feinberg, A. P. & Vogelstein, B. (1983) *Anal. Biochem.* **132**, 6–13.
17. Sanger, F., Nicklen, S. & Coulson, A. R. (1977) *Proc. Natl. Acad. Sci. USA* **74**, 5463–5467.
18. Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J. & Rutter, W. J. (1979) *Biochemistry* **18**, 5294–5299.
19. Werner, D., Chemla, Y. & Herzberg, M. (1984) *Anal. Biochem.* **141**, 329–336.
20. Mueckler, H. & Pitot, H. C. (1985) *J. Biol. Chem.* **260**, 12993–12997.
21. Huynh, T. V., Young, R. A. & Davis, R. W. (1985) in *DNA Cloning*, ed. Glover, D. M. (IRL, Oxford), Vol. 1, pp. 49–78.
22. Beutler, E., West, C. & Blume, K.-G. (1976) *J. Lab. Clin. Med.* **88**, 328–333.
23. Borgese, N., Pietrini, G. & Gaetani, S. (1987) *J. Clin. Invest.* **80**, 1296–1302.
24. Melton, D. A., Krieg, P. A., Rebagliati, M. R., Maniatis, T., Zinn, K. & Green, M. R. (1984) *Nucleic Acids Res.* **12**, 7035–7056.
25. Green, M. R., Maniatis, T. & Melton, D. A. (1983) *Cell* **32**, 681–694.
26. Zinn, K., Di Maio, D. & Maniatis, T. (1983) *Cell* **34**, 865–879.
27. Kozak, M. (1983) *Microbiol. Rev.* **47**, 1–45.
28. Seed, B. (1982) in *Genetic Engineering*, eds. Setlow, J. & Hollander, A. (Academic, New York), Vol. 4, pp. 91–102.
29. Okada, Y., Frey, A. B., Guenther, T. M., Oesch, F., Sabatini, D. D. & Kreibich, G. (1982) *Eur. J. Biochem.* **122**, 393–402.
30. Lederer, F., Ghir, R., Guiard, B., Cortial, S. & Ito, A. (1983) *Eur. J. Biochem.* **132**, 95–102.
31. Slaughter, S. R. & Hultquist, D. E. (1979) *J. Cell Biol.* **83**, 231–239.